Halifax, Canada
Halifax, Canada

Time filter

Source Type

The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject.

News Article | May 10, 2017
Site: www.marketwired.com

HALIFAX, NOVA SCOTIA--(Marketwired - May 10, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today released its financial and operational results for the first quarter ended March 31, 2017. "Immunovaccine's accomplishments this quarter underscore our clinical strategy, which is to focus on combination immuno-oncology therapies incorporating our lead candidate, DPX-Survivac," said Frederic Ors, Immunovaccine's Chief Executive Officer. "Our objective is to confirm preliminary observations that DPX-Survivac may work synergistically to increase the vulnerability of hard-to-treat tumors, improving the anti-cancer responses of today's best monotherapies, including anti-PD-1 agents. From our announcement of the early data in our triple combination immuno-therapy with Incyte, to the planned Phase 2 trial in combination with Merck's leading anti-PD 1 drug, we were pleased to show how our lead candidate, DPX-Survivac, achieved several milestones on the path to addressing an important unmet medical need." Operational Highlights of the First Quarter 2017 Include: The Company prepares its unaudited interim condensed consolidated financial statements in accordance with Canadian generally accepted accounting principles as set out in the Chartered Professional Accountants of Canada – Accounting Part I ("CPA Canada Handbook"), which incorporates International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). The net loss and comprehensive loss of $2,369,000 for the quarter ended March 31, 2017 ("Q1 Fiscal 2017") was $518,000 higher than the net loss and comprehensive loss for the three months ended March 31, 2016 ("Q1 Fiscal 2016"). This relates mainly to a $63,000 increase in research and development costs, a $60,000 increase in business development and investor relations costs, a $189,000 increase in general and administrative expenditures, a decrease in revenue of $65,000 and a $141,000 increase in accreted interest. At March 31, 2017, Immunovaccine had cash and cash equivalents of $11,774,000 and working capital of $11,870,000 as compared to $13,547,000 in cash and $12,982,000 in working capital at December 31, 2016. As of May 10, 2017, the number of issued and outstanding common shares was 119,863,293. As of May 10, 2017, the number of stock options outstanding was 5,064,947, the number of outstanding deferred share units was 399,842 and the number of outstanding warrants was 7,617,683. Immunovaccine's unaudited interim condensed consolidated financial statements for March 31, 2017, filed in accordance with IFRS, and the management discussion and analysis (MD&A), will be available at www.sedar.com. Voting Results of Annual and Special Meeting of Shareholders of the Company Immunovaccine also announced the voting results of the annual and special meeting (the "Meeting") of shareholders of the Company (the "Shareholders") held today in Halifax, Nova Scotia, each of the 8 nominees listed in the Management Information Circular filed with regulatory authorities were elected as directors of the Corporation. Based on the proxies received and the votes on a show of hands, the following individuals were elected as directors of the Corporation until the next annual shareholders' meeting. Accordingly, the results are set out below: All other resolutions provided for in the Management Information Circular were duly passed and as such a report on the voting results will be filed today with the Canadian securities regulatory authorities at www.sedar.com. Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com. This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report. 1: Introduction - Goals and Objectives - Reasons for Doing This Study - Intended Audience - Scope of The Study - Information Sources for the Technology Assessment - Forecasting Methodology - Geographic Breakdown 3: Overview - Past and Present of Cancer Immunology - What is Cancer? - Treating Cancer - Challenges in Treating Cancer - Cancer and the Immune System - Immunotherapy - Towards Combination Immunotherapy - Focusing on Cell-mediated Adaptive Immunity - Fine Tuning Versus Boosting Cancer Immunity - Early Versus Advanced Stage Cancer Immunotherapy - Personalized Treatment Paradigm - Clinically Significant Types of Cancers - Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology 4: Overview of Cancer Immunotherapy - Immune System and Immunotherapy - Therapeutic Monoclonal Antibodies - Checkpoint Inhibitors - Biological Response Modifiers - Vaccines - Other - Expanded Information on Selected Product Candidates and Recent Regulatory Applications 7: Company Profiles - Abbvie Inc. - Adaptimmune - Aduro Biotech - Advantagene - Advaxis Immunotherapies - Amgen - Argos Therapeutics - Ariad Pharmaceuticals - Arog Pharmaceuticals - Aserta Pharmaceuticals - Astellas - Astrazeneca - Avax Technologies - Bavarian Nordic - Bayer Healthcare - Biovex - Boehringer Ingelheim - Boston Biomedical - Bristol-Myers Squibb - Cell Medica - Celldex Therapeutics - Celgene Corp. - Chugai - Cold Genesys - Daiichi Sankyo Co. - Dendreon - Dnatrix - Eisai - Eli Lilly - F Hoffmann La Roche AG - Genelux - Gilead Sciences Inc. - Glaxosmithkline Plc - Hanmi Pharmaceutical - Heat Biologics - Immune Design - Immunocellular Therapeutics Ltd. - Immunomedics Inc. - Immunovaccine Inc. - Immunovative Therapies - Incyte Ciorp. - Inovio Pharmaceuticals Inc. - Janssen Pharmaceuticals - Kadmon Pharmaceuticals Corp. - Kite Pharmaceuticals Inc. - Kyowa Hakko Kirin Co. Ltd. - Ligand Pharmaceuticals Inc. - Lion Biotechnologies - Lokon Pharmaceuticals AB - Medimmune - Merck & Co. - Merck Kgaa - Merck Serono - Medigene AG - Mirati Therapeutics - Multivir Inc. - Newlink Genetics - Northwest Biotherapeutics - Novartis Pharma Services AG - Oncolys Biopharma Inc. - Oncolytics Biotech Inc. - Oncomed Pharmaceuticals Inc. - Oncos Therapeutics Ltd. - Ono Pharmaceutical Co. - Otsuka Pharmaceutical Co., Ltd. - Pfizer Inc. - Plexxikon Inc. - Portola Pharmaceuticals Inc. - Provectus Biopharmacueticals Inc. - Psioxus Therapeutics Ltd. - Sanofi SA - Seattle Genetics - Shanghai Sunway Biotech Co. Ltd. - Shenzhen Sibiono Gentech - Sillajen Biotherapeutics Inc. - Spectrum Pharmaceuticals - Takara Bio Inc. - Takeda Co. Ltd. - Tapimmune Inc. - Targovax - Teva Pharmaceutical Industries Ltd. - TG Therapeutics Inc. - Tracon Pharmaceuticals Inc. - Transgene - VCN Biosciences - Ventirx - Verastem Inc. - Viralytics Ltd. - Virttu Biologics Ltd - Vyriad - Western Oncolytics Ltd. For more information about this report visit http://www.researchandmarkets.com/research/fpck42/cancer_immunology To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-immunology-and-oncolytic-virology-technologies-and-markets-report-2017-market-should-reach-965-billion-by-2021-from-730-billion-in-2016-at-a-cagr-of-57---research-and-markets-300458203.html

News Article | May 25, 2017
Site: marketersmedia.com

— RnRMarketResearch.com adds “Peritoneal Cancer - Pipeline Review, H1 2017” to its store providing an overview of the Peritoneal Cancer therapeutic pipeline with comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. Complete report on H1 2017 pipeline review of Peritoneal Cancer spread across 759 pages is available at http://www.rnrmarketresearch.com/peritoneal-cancer-pipeline-review-h1-2017-market-report.html . Peritoneal Cancer Pipeline report also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 3-V Biosciences Inc, AbbVie Inc, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advenchen Laboratories LLC, Altor BioScience Corp, Amgen Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Celsion Corp, CerRx Inc, Clovis Oncology Inc, Critical Outcome Technologies Inc, Dr. Reddy's Laboratories Ltd, Eisai Co Ltd, Eli Lilly and Company, EpiThany Inc, Esperance Pharmaceuticals Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Gene Techno Science Co Ltd, Genelux Corp, Genentech Inc, Genor BioPharma Co Ltd, Glycotope GmbH, Gradalis Inc, Hemispherx Biopharma Inc, ImmunoGen Inc, Immunovaccine Inc, Incyte Corp, Innate Pharma SA, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Lidds AB, Mabion SA, MabVax Therapeutics Holdings Inc, Mateon Therapeutics Inc, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, MolMed SpA, Mycenax Biotech Inc, NewLink Genetics Corp, Novartis AG, Novogen Ltd, Oasmia Pharmaceutical AB, OBI Pharma Inc, Oncobiologics Inc, Oncolix Inc, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Oxford BioMedica Plc, Pfizer Inc, Pharma Mar SA, Polaris Pharmaceuticals Inc, PsiOxus Therapeutics Ltd, Richter Gedeon Nyrt, Samyang Holdings Corp, Sanofi, Sanofi Pasteur SA, Sotio AS, Syndax Pharmaceuticals Inc, TapImmune Inc, Tyrogenex Inc, Vascular Biogenics Ltd, VentiRx Pharmaceuticals Inc, Verastem Inc Get Discount on This Report At http://www.rnrmarketresearch.com/contacts/discount?rname=1001938 (This report is available at upto 25% Discount till 02 June 2017.) Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy. Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 12, 60, 36, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 1 molecule, respectively. Direct Purchase of This Research Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1001938 . Scope of this report: The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer and reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Peritoneal Cancer. About Us: RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.rnrmarketresearch.com/peritoneal-cancer-pipeline-review-h1-2017-market-report.html

Loading Immunovaccine collaborators
Loading Immunovaccine collaborators